Statin as Regulatory T Cell Modulator in COPD With Early Disease

Early detection and intervention are critical to preventing or slowing the progression of COPD to advanced stages. However, no disease-modifying agent is currently available. COPD smokers exhibit reduced regulatory T (Treg) cell levels in lung tissue, whereas normal smokers demonstrate higher levels. Treg cells may mitigate lung damage by suppressing cytolytic CD8+ T-cells. Forced expiratory volume in 1 second (FEV₁) correlates with Treg cell levels in COPD. In lung tissue from surgically removed centrilobular emphysema lungs, granzyme (Gzm) B+ cells correlated with FEV₁. Gzm B is considered a potential functional marker for Treg cells. An animal study found that statins increase Treg cell proliferation and Gzm B secretion. Statins are known to increase Treg cell activity in human. This review synthesized clinical evidence on the immunomodulatory effects of statins in COPD, with particular emphasis on disease stage, duration of treatment, and timing of statin initiation relative to smoking exposure. Findings from prospective clinical trials in COPD have been inconsistent. In contrast, retrospective studies have demonstrated apparent advantages of statins. Notably, participants in prospective trials often had more advanced airflow limitation and shorter durations of statin exposure. Experimental evidence in animals indicates that statin administration initiated 3 months after smoking was ineffective, whereas treatment commenced at the onset of exposure attenuated airway disease. These findings suggest that statin therapy may have disease-modifying potential when initiated in COPD patients with early disease. Prospective trials focusing on this population are urgent to determine whether statins can prevent or slow disease progression of COPD.